In the relentless battle against cancer, the quest for more effective and less invasive treatments has led to significant scientific breakthroughs. Among the most promising innovations in this domain is Cytotron therapy, a non-invasive technology that has opened new frontiers in cancer care. This groundbreaking approach, leveraging Rotational Field Quantum Magnetic Resonance (RFQMR), offers a beacon of hope for those navigating the challenging journey of cancer treatment.
The Advent of Cytotron Therapy: A Paradigm Shift
Cytotron therapy emerges as a revolutionary approach, marking a paradigm shift from traditional cancer treatments. This therapy operates on the principle of quantum magnetic resonance. This technology targets cancerous cells directly, aiming to inhibit their growth and reduce metastasis, all while preserving the integrity of surrounding healthy tissues.
In the relentless pursuit of innovative solutions for cancer treatment, Cytotron has emerged as a groundbreaking technology with the potential to reshape the landscape of oncology. Its recent Breakthrough Device Designation by the United States Food and Drug Administration (USFDA) underscores the significance of this advancement. Cytotron’s designation as a Breakthrough Device signifies its transformative impact on cancer care.
The science behind Cytotron therapy is as fascinating as it is hopeful. By focusing Fast Radio Bursts (FRBs) on cancerous cells, it affects the cellular signaling that controls cell growth and death. This precision not only holds the promise of higher efficacy but also significantly minimizes the adverse side effects commonly associated with cancer treatments.
Cytotron has evolved using Magnetic Resonance Imaging (MRI) based on intrinsic proton density (PD) measurements of target tissue to manipulate biophysical cellular signaling. Highly complex Fast Radio Bursts (FRB) in the safe radio frequency range, in the presence of controlled, high, instantaneous Magnetic Resonance, is precisely focused on target tissues to alter the Transmembrane potential (TMP) of cells which triggers apoptosis (programmed cell death) and stops growth of solid tumors.
CYTOTRON Therapy – Reengineering the body’s tumor suppression mechanism
Cancer is a disorder characterized by the uncontrolled growth and spread of abnormal cells in the body. Normally, cells grow, divide, and die in a controlled manner (Apoptosis). Apoptosis, often referred to as programmed cell death, is a highly regulated process by which cells self-destruct in a controlled manner after the life cycle. This process plays a crucial role in various physiological processes, including development, tissue homeostasis, and the elimination of damaged or cancerous cells.
Apoptosis can be triggered by various internal and external signals. TP53, also known as the tumor protein 53 or simply p53, is a crucial protein involved in regulating apoptosis. Its role in apoptosis is primarily as a tumor suppressor, acting to prevent the proliferation of cells with damaged DNA or other abnormalities that could lead to cancer.
However, in cancer, this process is disrupted and p53 and its satellite proteins are often deregulated, leading to the accumulation of abnormal cells that form tumors and invade surrounding tissues. The intricate network of p53 and its satellite proteins plays a critical role in maintaining genomic stability, preventing cancer development, and regulating cellular fate decisions in response to various stress signals. Deregulation of TP53 is commonly observed in many types of cancer.
Naturally, these cancer cells don’t know when to stop multiplying and eventually progress to grow within an organ in the body. As they grow, they land up with a resource crunch. Then, these cells look at forming new colonies and start spreading with their “survival instincts” taking over. Cancer produces a very special kind of cell, called EMT cells or cancer stem cells (CSCs), that spread to another location and then it builds up new colonies through a process called metastasis. During metastasis, cancer cells break away from the primary tumor and travel through the bloodstream or lymphatic system to other parts of the body. Once they reach a new location, they can form secondary tumors, continuing the cycle of uncontrolled growth and spread.
As the cancer is growing, the body’s immune system does not attack it. On the contrary, it protects the cancer tissue. Cancer cells take advantage of this situation, and conquer different organs of the body, until the body cannot function normally.
Cytotron is intended to non-invasively re-activate the body’s tumor suppression mechanism by targeting high precision and calibrated doses of fast radio bursts (FRB) – non-ionising, non-thermal electromagnetic waves at the tumor site. This triggers the production of new tumor suppressing nucleoproteins, predominantly upregulating p53, which determines and flags that the cell is old enough to die.
Metastasis is a major challenge in cancer treatment, as it makes the disease more difficult to manage and reduces the effectiveness of localized therapies such as surgery or radiation.
Depending on which stage of cancer is being treated at, Cytotron Therapy stops the cancer cells from spreading (Metastasis) from that stage. If Cytotron therapy is used at an early stage, the cancer gets arrested at that point. Once we stop the tumor from growing and spreading, there are other modalities that can manage the disease further.
Cytotron acts on the mitochondrial membrane and interfere with communication between the gene transcription machinery and the protoplasmic glycoproteinic complexes involved in the promotion of cellular mitosis. Based on the outcomes reported in treating malignant lesions, the Cytotron induces such alterations of the TMP in a controlled manner, to modify cellular command and control and alter cellular activity to stabilize and arrest tumor progression.
A New Hope: The Advantages of Cytotron Therapy
The introduction of Cytotron therapy into the cancer treatment landscape brings numerous advantages. Its non-invasive nature and without any adverse side effects, stands at the forefront, offering a treatment option with fewer complications and a quicker return to daily life.
Furthermore, the targeted approach of Cytotron therapy aligns with the growing trend towards personalized medicine in oncology. By focusing on the unique characteristics of each patient’s cancer status, Cytotron therapy can be more effective and less harmful. This precision medicine approach ensures that the battle against cancer is not just a blanket strategy but a tailored fight, respecting the individuality of each patient’s condition and whole person integrative approach.
Pediatric cancer presents a unique set of difficulties and challenges, both for the children affected and their families. A recent Clinical Study on Pediatric Cancer patients showed QMRT was well tolerated in a series of pediatric patients with Diffuse Brainstem Glioma (DBG), and there was a statistically significant increase in overall survival when using historical controls.
The potential of Cytotron in the realm of medical science is vast and holds promise for the future of cancer treatment. As research continues and the technology evolves, Cytotron may become a pivotal player in the broader landscape of oncology. Here are some key areas where Cytotron could make a lasting impact:
- Early-Stage Intervention: Cytotron’s precision-guided approach makes it well-suited for early-stage cancer intervention. Detecting and treating cancer at its inception can significantly enhance the chances of successful outcomes. Cytotron’s application in addressing early stage cancer has an excellent prognosis.
- Combination Therapies: Cytotron treatment can potentially be integrated with other existing cancer therapies, creating a comprehensive approach that tackles the disease from multiple angles. This synergy could lead to enhanced treatment efficacy and better outcomes even in 4th stage or palliative care patients.
- Expanding Treatment Options: The non-invasive nature of Cytotron makes it an attractive option for patients who may not be suitable candidates for conventional treatments like chemotherapy, etc, due to age, health conditions, or other factors. This expansion of treatment option ensures that a broader spectrum of patients can benefit from cutting-edge cancer care.
- Reduced Healthcare Costs: By minimizing the need for invasive surgeries, long hospital stays, and extensive recovery periods, Cytotron has the potential to contribute to cost-effective cancer care. This not only benefits patients but also alleviates the economic burden on healthcare systems.
However, non-solid tumors like Leukemia and Multiple Myeloma cannot be treated with Cytotron.
Below are the contraindications:
- Patients with electrically, magnetically or mechanically activated implants (cardiac pacemakers, bio-stimulators, neuro-stimulators, cochlear implants)
- Pregnancy & lactating mothers
- MRI incompatible implants
- Critically ill patients (like needing life support)
- Mentally challenged patients
- Patients who have inability to lie in a supine position with minimal movement for the duration of the therapy (1 hour)
- Any other medical contra-indicatives found during screening and evaluation by the medical team.
Approvals & Regulatory status
- CYTOTRON® is a breakthrough, patented, novel medical device which has received relevant safety clearances.
- CYTOTRON® was granted “Breakthrough Device Designation’ by US FDA for treatment of Breast, Liver and Pancreatic Cancers.
- CYTOTRON® is licensed in India by Central Drugs Standard Control Organisation (CDSCO), Ministry of Health and Family Welfare, Govt of India, as a therapeutic device for treating protein linked abnormally regenerating disorders (Cancer) enabling tissue apoptosis and preventing metastasis.
Precision Medicine in Action: The Cytotron Therapy Protocol Explained
- The patient’s medical history and reports are scrutinized by the Medical team and may be advised for pre-treatment check-ups and blood tests as required.
- Patient clinical evaluation (either in person or online)
- A whole-body MRI for tissue proton density determination is done to compute individualized dosimetry to target solitary (Single lesion /Brain) or multiple regions of interest (multiple lesion / widespread metastasis) in the whole body simultaneously.
- A 2D Proton Density (PD) sequence of the tumor is obtained on film and copied by the radiologist in a DVD for use at the treatment center for dose planning
- A very low intensity image guided surface marking of the Region of Interest (target tissue) is made by the radiologist.
- The CD containing PD images is loaded into the Cytotron Central Control Unit (CCU) and the region(s) of interest is/are identified. The largest and smallest diameter of each lesion is marked. A margin of 1-2 mm beyond the target area is marked to include any infiltrating, rapidly growing tumor cells around the lesion are included in the region of interest.
- The sequence of dose planning is set in motion automatically by the Central Control Unit, applying pre-planned proprietary algorithms
- The patient is treated for one hour every day for a period of 28 consecutive days without a break. If there is break for more than 24 to 48 hours before the completion of the treatment period, the treatment has to start all over again.
- Patient will be reviewed periodically for 12 months from the date of completion of the treatment based on the blood reports, PET CT / MRI to compare and study efficacy of the treatment in terms of tumor metabolic activity, measureable changes in dimensions, tumor volume and signal intensity differences between pre and post-treatment of targeted lesions and overall wellbeing of the patient.
GLIA INTEGRATED HEALTHCARE : Integrating Cytotron Therapy into Comprehensive Cancer Care
As we stand on the brink of a new era in cancer treatment, the integration of Cytotron therapy into comprehensive care plans is gaining momentum. Clinical trials and research are continuously unveiling the efficacy and safety of this therapy, making it a compelling option for patients and healthcare providers alike. These studies are critical for not only validating the effectiveness of Cytotron therapy but also for exploring how it can be combined with other treatments, such as immunotherapy, to enhance patient outcomes and as adjuvant therapy with chemotherapy, radiation therapy or hormone therapy to lower the risk of side effects and the cancer recurrence (returning).
The Path Forward: Accessibility and Innovation
Despite the promise of Cytotron therapy, challenges remain in making this therapy widely accessible. Issues such as cost for setting up new centers, cashless insurance coverage, lack of awareness, need for specialized equipment can be barriers to widespread adoption. However, ongoing research, advocacy, and policy development are key to overcoming these hurdles, ensuring that more patients can benefit from this innovative treatment.
Conclusion: A Brighter Future in Cancer Treatment
Cytotron therapy represents more than just a medical innovation; it symbolizes hope—a hope for non- invasive, non-toxic and more effective cancer treatments. As we continue to explore and expand the horizons of cancer care, technologies like Cytotron therapy play a pivotal role in shaping a future where cancer treatment is not only about quality of life but also surviving.
In embracing the potential of such advancements, it’s crucial for patients, healthcare providers, and the broader community to stay informed and engaged. The journey toward revolutionizing cancer treatment is a collective effort, one that requires collaboration, curiosity, and courage.
Ready to explore a groundbreaking approach to cancer treatment? Discover the transformative potential of the Cytotron Therapy. Click here to schedule an appointment or call +91 90198 56034
